Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Ductal Breast Carcinoma In Situ|Estrogen Receptor Positive
Interventions: DRUG: Afimoxifene|OTHER: Laboratory Biomarker Analysis|OTHER: Placebo|OTHER: Placebo|DRUG: Tamoxifen Citrate
Sponsor: Northwestern University
Collaborators: National Cancer Institute (NCI)|BHR Pharma, LLC